EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Cash from Operating Activities
EyePoint Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Cash from Operating Activities
$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is EyePoint Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
1.9m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Cash from Operating Activities amounts to 1.9m USD.